Knowledge

On July 16, 2025, AstraZeneca presented interim results of the CARES Phase III program for the treatment of AL amyloidosis. In the overall group of patients with advanced disease (Mayo stages IIIa/IIIb), the antibody anselamimab could not significantly improve the primary endpoint – a combined assessment of overall survival and cardiovascular hospitalizations. However, in a predefined subgroup, it showed a clinically relevant extension of survival and fewer cardiac hospitalizations compared to placebo. The 406 study participants received anselamimab or placebo in addition to standard therapy; the treatment was well tolerated. Anselamimab is a novel anti-fibril antibody for the reduction of amyloid deposits; further analyses are ongoing, and the data will be presented at scientific conferences and submitted to regulatory authorities.

Our information brochures about Transthyretin Amyloidosis with Polyneuropathy (ATTR-PN) are available. These comprehensive guides provide important information about this form of amyloidosis.